PECAM1 and neoplasm: Although the antibody did not affect tumor cell growth in vitro, it led to a significant growth delay in several xenograft models, including breast, ovarian carcinoma and particularly melanoma, associated with a reduced number of blood vessels as evidenced by CD31/CD105 staining, indicating that the antibody targets tumor vasculature in vivo [100].